SEC Form 4 · accession 0001909680-26-000002
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francesca Barone
Officer — Chief Scientific Officer
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001841387
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 29, 2026 | S | 23,447 | $10.0554 | D | 77,362 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.